Journal of Istanbul Faculty of Medicine

SUBMITINFORMATION
EnglishTürkçe

Review


DOI :10.26650/IUITFD.2020.0056   IUP :10.26650/IUITFD.2020.0056    Full Text (PDF)

IMMUN RESPONSES IN COVID-19

Bülent Çakal

The Coronavirus disease 19 (COVID-19) pandemic, which is the etiological agent of a severe acute respiratory syndrome-associated coronavirus (SARS-CoV-2), has influenced the whole world with the current and possible results. COVID-19 has very unique virological, clinical and immunological characteristics. In COVID19, immune responses can vary widely, ranging from responses that allow control of the infection to pulmonary thrombosis characterized by sudden and rapidly developing intense inflammation and storm of cytokenemia. This review aims to examine scientific data about immunopathogenesis of COVID-19  

Keywords: COVID-19, SARS-CoV-2, immunopathology, immune dysregulation, macrophage activation, interleukin-6, cytokine/ chemokine storm, hrombo inflammator syndrome
DOI :10.26650/IUITFD.2020.0056   IUP :10.26650/IUITFD.2020.0056    Full Text (PDF)

COVID-19’DA İMMÜN YANITLAR

Bülent Çakal

Şiddetli akut solunum sendromu ilişkili bir coronavirüsün (Severe acute respiratory syndrome-related coronavirus 2; SARS-CoV-2) etiyolojik etkeni olduğu coronavirüs hastalığı 19 (coronavirus disease 19; COVID-19) pandemisi mevcut ve olası sonuçları açısından tüm dünyayı etkisi altına almıştır. COVID-19 oldukça özgün virolojik, klinik ve immünolojik karakteristik özelliklere sahiptir. COVID19’da bağışık yanıtlar enfeksiyonunun kontrol altına alınmasına imkan sağlayan yanıtlardan ani ve hızlı gelişen yoğun enflamasyon ve sitokin fırtınası ile karakterize pulmoner trombozise kadar uzunan geniş bir yelpazede değişkenlik gösterebilmektedir. Bu derlemede COVID-19’un immünpatogenizine ilişkin bilimsel verilerin irdelenmesi amaçlanmıştır

Keywords: COVID-19, SARS-CoV-2, immünpatoloji, immün regülasyon kaybı, makrofaj aktivasyonu, interlökin-6, sitokin/kemokin fırtınası, tromboenflamatuvar sendrom

PDF View

References

  • 1 . Zhou P, Yan X-L, Wang X-G, Hu B, Zhang L, Zhang W. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270-3. [CrossRef] google scholar
  • 2 . Gorbalenya AE, Baker SC, Baric RS, Groot RJ, Drosten C, Haagmans BL, et al. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndromerelated coronavirus: classifying. Nat Microbiol 2020;5(4):536-54. [CrossRef] google scholar
  • 3 . Liu Y, Ning Z, Chen Y, Guo M, Liu Y, Gali NM. et al. Aerodynamic Characteristics and RNA Concentration of SARS-CoV-2 Aerosol in Wuhan Hospitals during COVID-19 Outbreak. biorRxiv 2020; [CrossRef] google scholar
  • 4 . Gu J, Han B, Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission. Gastroenterology 2020;158(6):1518-19. [CrossRef] google scholar
  • 5 . Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W. et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. The Lancet 2020;395:809-81. [CrossRef] google scholar
  • 6 . Guan WJ. Ni, Z-y, Hu Y, Liang W-h, Ou C-q, He J-x. et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20. [CrossRef] google scholar
  • 7 . Yang J, Zhenga Y, Goua X, Pua K, Chena Z, Guo Q. et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. International Journal of Infectious Diseases 2020;94:91-95. [CrossRef] google scholar
  • 8 . Chen N, Zhou M, Dong Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507-13. [CrossRef] google scholar
  • 9 . Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. Nature 2020;581(7809):465-9. [CrossRef] google scholar
  • 10 . Goyal A, Fabian C-O, E, Schiffer J.T. Potency and timing of antiviral therapy as determinants of duration of SARS CoV-2 shedding and intensity of inflammatory response. MedRxiv 2020; [CrossRef] google scholar
  • 11 . Chang, Mo G, Yuan X, Tao Y, Peng X, Wang F-S. et al. Time Kinetics of Viral Clearance and Resolution of Symptoms in Novel Coronavirus Infection. Am J Respir Crit Care Med 2020;201(9):1150-52. [CrossRef] google scholar
  • 12 . Lin WH, Kouyos RD, Adams RJ, Grenfell BT, Griffin DE. Prolonged persistence of measles virus RNA is characteristic of primary infection dynamics. Proc Natl Acad Sci U S A 2012;109:14989-94. [CrossRef] google scholar
  • 13 . Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with Different Severity: A Multi-center Study of Clinical Features. Am J Respir Crit Care Med 2020;201(11):1380-8. [CrossRef] google scholar
  • 14 . Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Science China Life Sciences 2020;63(3):364-74. [CrossRef] google scholar
  • 15 . Fogarty H, Townsend L, Cheallaigh CN, Bergin C, Martin-Loeches I, Browne P, et al. COVID-19 Coagulopathy in Caucasian patients. Br J Haematol 2020; 189(6):1060-1. [CrossRef] google scholar
  • 16 . Xu, Y-H, Dong J-H, An W-M, Lv X-Y,Yin X-P, Zhang J-Z, et al. Clinical and computed tomographic imaging features of Novel Coronavirus Pneumonia caused by SARS-CoV-2. J Infect 2020;80(4):394-400. [CrossRef] google scholar
  • 17 . Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusinfected pneumonia in Wuhan, China. JAMA 2020;323;1061-69. [CrossRef] google scholar
  • 18 . Zhang B, Zhou X, Qiu Y, Feng F, Feng J, Jia Y. et al. Clinical characteristics of 82 death cases with COVID-19. medRxiv 2020; [CrossRef] google scholar
  • 19 . Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol 2020;20(5):269-2-70. [CrossRef] google scholar
  • 20 . Tay MZ, Poy CM, Renia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nature Rew İmmuno 2020;20(6):363-74. [CrossRef] google scholar
  • 21 . Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. Med Virol 2020;92(4):424-32. [CrossRef] google scholar
  • 22 . Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 2020;180:1-12. [CrossRef] google scholar
  • 23 . Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020;367:1260-3. [CrossRef] google scholar
  • 24 . Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N. et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ace2) converts angiotensin I to angiotensin 1-9. Circ Res 2000;87(5):E1-9. [CrossRef] google scholar
  • 25 . Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B. et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nature Med 2005;1:875-9. [CrossRef] google scholar
  • 26 Zhang H, Zhou P, Wei Y, Yue H, Wang Y, Hu M, et al Histopathologic changes and SARS- CoV-2 immunostaining in the lung of a patient with COVID-19 Ann Intern Med 2020;172(9):629-32 [CrossRef] google scholar
  • 27 Yang, M Cell pyroptosis, a potential pathogenic mechanism of 2019-nCoV infection SSRN 2020;10 2139/ssrn 3527420 [CrossRef] google scholar
  • 28 Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al Dysregulation of immune response in patients with COVID-19 in Wuhan, China Clin Infect Dis 2020;71(15):762-8 [CrossRef] google scholar
  • 29 Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, et al Complex immune dysregulation in COVID-19 patients with severe respiratory failure Cell Press 2020;27(6):992-1000 e3 [CrossRef] google scholar
  • 30 Ye Q, Wang B, Mao J The pathogenesis and treatment of the Cytokine Storm’ in COVID-19 J Infect 2020;80(6):607-13 [CrossRef] google scholar
  • 31 Herold T, Jurinovic PV, Arnreich C, Hellmuth JC, Bergwelt-Baildon MV, Klein M Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients medRvix 2020; [CrossRef] google scholar
  • 32 Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al COVID-19: consider cytokine storm syndromes and immunosuppression Lancet 2020;395(10229):1033-4 [CrossRef] google scholar
  • 33 Ciceri F, Beretta L, Scandroglio A M, Colombo S, Landoni G, Ruggeri A, et al Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis Crit Care Resusc 2020;22(2):95-7 google scholar
  • 34 Randall RE Goodbourn S Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures J Gen Virol 2008;89:1-47 [CrossRef] google scholar
  • 35 Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, et al Immunology of COVID-19: current state of the science Immunity 2020;52(6):910-41 [CrossRef] google scholar
  • 36 Chen W Royer WE Structural insights into interferon regulatory factor activation Cell Signal 2010;22:883-87 [CrossRef] google scholar
  • 37 Sun L, Xing Y, Chen X, Zheng Y, Yang Y, Nichols DB, et al Coronavirus papain- like proteases negatively regulate antiviral innate immune response through disruption of STING- mediated signaling PLoS One 2012;7:e30802 [CrossRef] google scholar
  • 38 Narayanan K, Huang C, Lokugamage K, Kamitani W, Ikegami T, Tseng C-TK et al Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene expression, including that of type I interferon, in infected cells J Virol 2008;82:4471-9 [CrossRef] google scholar
  • 39 Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al Speciality Collaboration, U K COVID-19: consider cytokine storm syndromes and immunosuppression Lancet 2020;395:1033-4 [CrossRef] google scholar
  • 40 Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H et al Clinical and immunological features of severe and moderate coronavirus disease 2019 J Clin Invest 2020;130(5):2620-9 [CrossRef] google scholar
  • 41 Huang L, Shi Y, Gong B, Jiang L, Liu X, Yang J, et al Blood single cell immune profiling reveals the interferon-MAPK pathway mediated adaptive immune response for COVID-19 medRxiv 2020; [CrossRef] google scholar
  • 42 Lei L, Qian H, Yang X, Zhou X, Zhang X, Zhang D, et al The phenotypic changes of YSTcells in COVID-19 patients . medRxiv 2020; [CrossRef] google scholar
  • 43 Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L et al Reduction and Functional Exhaustion of T Cells in Patients with Coronavirus Disease 2019 (COVID-19) medRxiv 2020; [CrossRef] google scholar
  • 44 Zheng H-Y, Zhang M, Yang C-X, Zhang N, Wang X-C, Yang X-P Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients Cell Mol Immunol 2020;17(5):541-3 [CrossRef] google scholar
  • 45 Shaw AC, Goldstein DR, Montgomery RR Age-dependent dysregulation of innate immunity Nature Reviews Immunology 2013;13:875-87 [CrossRef] google scholar
  • 46 Zhao J, Yuan Q, Wang H, Liu W, Liao, Su Y, Wang X et al Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 Clin Infect Dis 2020;ciaa344 [CrossRef] google scholar
  • 47 Perlman S & Dandekar AA Immunopathogenesis of coronavirus infections: implications for SARS Nat Rev Immunol 2005;5:917-27 [CrossRef] google scholar
  • 48 Sanders JM, Monogue ML, Tomasz Z, Jodlowski TZ, Cutrell JB Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19) JAMA 2020;323(18):1824-36 [CrossRef] google scholar
  • 49 Liu S, Lien C, Selvaraj P Wang TT Evaluation of 19 antiviral drugs against SARS-CoV-2 Infection bioRxiv 2020; [CrossRef] google scholar
  • 50 McKee DL, Sternberg A, Naujokat C, et al Candidate drugs against SARS-CoV-2 and COVID-19 Pharmacol Res 2020;157:104859 [CrossRef] google scholar

Citations

Copy and paste a formatted citation or use one of the options to export in your chosen format


EXPORT



APA

Çakal, B. (2021). IMMUN RESPONSES IN COVID-19. Journal of Istanbul Faculty of Medicine, 84(2), 256-263. https://doi.org/10.26650/IUITFD.2020.0056


AMA

Çakal B. IMMUN RESPONSES IN COVID-19. Journal of Istanbul Faculty of Medicine. 2021;84(2):256-263. https://doi.org/10.26650/IUITFD.2020.0056


ABNT

Çakal, B. IMMUN RESPONSES IN COVID-19. Journal of Istanbul Faculty of Medicine, [Publisher Location], v. 84, n. 2, p. 256-263, 2021.


Chicago: Author-Date Style

Çakal, Bülent,. 2021. “IMMUN RESPONSES IN COVID-19.” Journal of Istanbul Faculty of Medicine 84, no. 2: 256-263. https://doi.org/10.26650/IUITFD.2020.0056


Chicago: Humanities Style

Çakal, Bülent,. “IMMUN RESPONSES IN COVID-19.” Journal of Istanbul Faculty of Medicine 84, no. 2 (May. 2024): 256-263. https://doi.org/10.26650/IUITFD.2020.0056


Harvard: Australian Style

Çakal, B 2021, 'IMMUN RESPONSES IN COVID-19', Journal of Istanbul Faculty of Medicine, vol. 84, no. 2, pp. 256-263, viewed 21 May. 2024, https://doi.org/10.26650/IUITFD.2020.0056


Harvard: Author-Date Style

Çakal, B. (2021) ‘IMMUN RESPONSES IN COVID-19’, Journal of Istanbul Faculty of Medicine, 84(2), pp. 256-263. https://doi.org/10.26650/IUITFD.2020.0056 (21 May. 2024).


MLA

Çakal, Bülent,. “IMMUN RESPONSES IN COVID-19.” Journal of Istanbul Faculty of Medicine, vol. 84, no. 2, 2021, pp. 256-263. [Database Container], https://doi.org/10.26650/IUITFD.2020.0056


Vancouver

Çakal B. IMMUN RESPONSES IN COVID-19. Journal of Istanbul Faculty of Medicine [Internet]. 21 May. 2024 [cited 21 May. 2024];84(2):256-263. Available from: https://doi.org/10.26650/IUITFD.2020.0056 doi: 10.26650/IUITFD.2020.0056


ISNAD

Çakal, Bülent. “IMMUN RESPONSES IN COVID-19”. Journal of Istanbul Faculty of Medicine 84/2 (May. 2024): 256-263. https://doi.org/10.26650/IUITFD.2020.0056



TIMELINE


Submitted15.05.2020
Accepted11.11.2020
Published Online30.03.2021

LICENCE


Attribution-NonCommercial (CC BY-NC)

This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.


SHARE




Istanbul University Press aims to contribute to the dissemination of ever growing scientific knowledge through publication of high quality scientific journals and books in accordance with the international publishing standards and ethics. Istanbul University Press follows an open access, non-commercial, scholarly publishing.